These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28230643)

  • 1. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T; Andres A; Toso C; Majno P; Squifflet JP
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 4. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Inhibition and Kidney Diseases.
    Ma MKM; Yung S; Chan TM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract]   [Full Text] [Related]  

  • 7. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
    Paoletti E
    Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Everolimus-based Immunosuppression to Decrease Cytomegalovirus Infection After Kidney Transplant.
    Malvezzi P; Jouve T; Rostaing L
    Exp Clin Transplant; 2016 Aug; 14(4):361-6. PubMed ID: 27041365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
    Fine NM; Kushwaha SS
    Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transplantation: time to rethink immunosuppression by mTOR inhibitors?
    Säemann MD; Remuzzi G
    Nat Rev Nephrol; 2009 Nov; 5(11):611-2. PubMed ID: 19855420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
    Bhat M; Watt KD
    Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
    Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
    BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer and mTOR Inhibitors in Transplant Recipients.
    de Fijter JW
    Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic review with meta-analysis: sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Grigg SE; Sarri GL; Gow PJ; Yeomans ND
    Aliment Pharmacol Ther; 2019 May; 49(10):1260-1273. PubMed ID: 30989721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Incidence of Ovarian Cysts in Women Receiving mTOR Inhibitors After Renal Transplantation.
    Bachmann F; Glander P; Budde K; Bachmann C
    J Womens Health (Larchmt); 2018 Mar; 27(3):394-398. PubMed ID: 29087803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.